Teladoc Health (NYSE:TDOC) Updates Q3 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.300–0.200 for the period, compared to the consensus estimate of -0.170. The company issued revenue guidance of $569.0 million-$609.0 million, compared to the consensus revenue estimate of $629.1 million. Teladoc Health also updated its FY 2026 guidance to -1.000–0.750 EPS.

Analysts Set New Price Targets

A number of research firms have issued reports on TDOC. Bank of America boosted their price target on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Canaccord Genuity Group raised their price objective on shares of Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Citigroup boosted their target price on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.57.

Teladoc Health Stock Performance

TDOC traded down $0.15 during midday trading on Wednesday, reaching $9.21. The company had a trading volume of 7,337,377 shares, compared to its average volume of 5,388,957. The business has a 50-day moving average of $8.16 and a two-hundred day moving average of $6.54. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.89. The company has a market cap of $1.66 billion, a P/E ratio of -9.50 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities research analysts predict that Teladoc Health will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Carlos Nueno sold 6,196 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider directly owned 57,671 shares in the company, valued at $440,029.73. This trade represents a 9.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares in the company, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 39,195 shares of company stock valued at $299,058. Company insiders own 0.70% of the company’s stock.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than analysts’ expected loss of $0.24. The earnings beat may support confidence in the company’s cost controls and near-term execution. Teladoc Health Reports Second Quarter 2026 Results
• Positive Sentiment: A valuation analysis argued that TDOC remains undervalued after its severe five-year decline, with discounted-cash-flow and market-multiple estimates indicating potential upside. This could attract value-oriented investors, although it is not a formal company forecast. Teladoc Health Stock Still Looks Undervalued
• Neutral Sentiment: Teladoc’s second-quarter results and accompanying materials provide investors with additional detail on operating metrics and management’s outlook. The earnings release itself did not eliminate concerns about the company’s longer-term path to profitability. Teladoc Health Earnings Slide Deck
• Negative Sentiment: Third-quarter guidance was below Wall Street expectations. Teladoc forecast an adjusted loss of $0.20–$0.30 per share versus a consensus loss of $0.17, while revenue guidance of $569 million–$609 million trailed the $629.1 million consensus estimate.
• Negative Sentiment: Full-year 2026 revenue guidance of approximately $2.4 billion was below the $2.5 billion analyst estimate. The company also remains unprofitable, reporting a negative 6.81% net margin and negative 11.45% return on equity.
• Negative Sentiment: A law firm issued a shareholder-investigation solicitation concerning possible fiduciary-duty issues involving Teladoc insiders. While unproven and promotional in nature, such announcements can add headline and litigation risk.

Hedge Funds Weigh In On Teladoc Health

Several large investors have recently made changes to their positions in the business. IFP Advisors Inc boosted its stake in shares of Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after acquiring an additional 3,210 shares during the period. PNC Financial Services Group Inc. raised its stake in Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 2,810 shares during the period. Van ECK Associates Corp raised its stake in Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock valued at $64,000 after purchasing an additional 4,607 shares during the period. Johnson Financial Group Inc. raised its stake in Teladoc Health by 41,045.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock valued at $76,000 after purchasing an additional 9,851 shares during the period. Finally, Cibc World Markets Corp purchased a new position in Teladoc Health in the 4th quarter worth approximately $82,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.